CA-AMAZENTIS
7.7.2022 14:09:09 CEST | Business Wire | Press release
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005266/en/
This study showed that treatment with Amazentis’ proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model.
These findings highlight Mitopure’s benefits for joint and mitochondrial health. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. This change is associated with age-related problems in various tissues, including osteoarthritis.
Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations. This new paper extends these benefits to cells in key joints such as the knee. Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.
“There are currently no effective solutions to treat osteoarthritis, a condition that is painful and limits the mobility of hundreds of millions of older people around the world. We tested Urolithin A in preclinical models of osteoarthritis and showed it has potential to both reduce inflammation and improve mitochondrial health, suggesting it may be a promising solution to support joint health and quality of life during aging,” says Martin Lotz MD, lead author on the paper and Professor of Molecular Medicine at Scripps Research in California, USA.
“This study is important and exciting as it shows, for the first time, that Urolithin A can increase mitochondrial health in living joint tissue,” says Davide D’Amico, first author on the paper and R&D Group Leader with Amazentis. “It highlights the important role of mitophagy in maintaining healthy functioning joints throughout life.”
In this study, Mitopure showed two key beneficial effects on cartilage cells from both healthy donors and OA patients:
- It significantly induced the recycling of aged and damaged mitochondria (mitophagy), assessed by imaging and molecular biology assays.
- It significantly increased the activity of mitochondria, measured as mitochondrial respiration, i.e. the ability of these organelles to consume oxygen and produce energy for our cells.
The second part of the study focused on the effect of supplementing Mitopure for 2 months on an experimental pre-clinical model of osteoarthritis. This model mimics the same symptoms experienced by people suffering from osteoarthritis, i.e. progressive cartilage damage, increased pain and inflammation.
- Analysis of knee joint sections by a pathologist indicated that supplementation with Mitopure decreased joint tissue degradation.
- Mitopure supplementation also reduced OA associated leg pain and exerted a mild anti-inflammatory effect on the disease model.
- Finally, better joint heath after Mitopure administration was associated with significantly enhanced mitochondrial health, including higher rates of removing worn out mitochondria (mitophagy) and increased regeneration of new, functional mitochondria.
"It was great to collaborate with Scripps Research to expand the body of evidence on the health applications of Urolithin A into joint health. It’s exciting to see a compound and mechanism of action that is benefiting both muscle and joints. We remain committed to delivering products that are clinically proven to have a meaningful impact on people’s health” says Chris Rinsch, CEO and co-founder of Amazentis.
The new results are significant because they add to growing evidence of the benefits of Mitopure on age-related conditions. Recent studies showed that Mitopure can improve mitochondrial health and counteract age-related muscle function decline in both healthy elderly and middle-aged overweight subjects. Together, the latest research supports a combined beneficial action of Urolithin A in both muscle and joints.
Doi: 10.1111/acel.13662
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure® Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279), Cell Reports Medicine
(Doi: 10.1016/j.xcrm.2022.100633) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure® linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure®
Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure® has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure® has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure® has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® is brought to you by the inventors of Mitopure®. This novel, science-first nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom